GluCare Integrated Diabetes Center, Dubai, United Arab Emirates.
Front Endocrinol (Lausanne). 2024 May 7;15:1355792. doi: 10.3389/fendo.2024.1355792. eCollection 2024.
Diabetes Mellitus, a global health challenge, affects 537 million individuals. Traditional management relies on periodic clinic visits, but technological advancements, including remote monitoring, offer transformative changes. Telemedicine enhances access, convenience, adherence, and glycemic control. Challenges include trust-building and limitations in face-to-face interactions. Integrating remote monitoring with in-person healthcare creates a hybrid approach. This study evaluates the impact on Type 2 Diabetes patients over 3 months.
A retrospective case-control observational study. Inclusion criteria involved previous Type 2 Diabetes diagnosis and a minimum 3-month GluCare model period with two physical visits. Patients in the case group had in-clinic visits, bi-weekly app engagement, and monthly body weight readings. Control group had in-clinic visits only. Outcomes measured included HbA1c, lipid profile, CV risk, eGFR, urine Albumin/Creatinine Ratio, Uric Acid, and CRP.
Case group showed significant HbA1c improvements (-2.19%), especially in higher baseline levels. Weight, BMI, LDL, total cholesterol, and CVD risk also improved. Controls showed smaller improvements. Higher digital interactions correlated with better outcomes. Patients with ≥11 interactions showed significant reductions in HbA1c (-2.38%) and weight (-6.00 kg).
The GluCare.Health hybrid model demonstrates promising outcomes in Type 2 diabetes management. The integration of in-clinic consultations with continuous remote monitoring leads to substantial improvements in glycemic control and clinical parameters. The study highlights the importance of patient engagement in achieving positive outcomes, with higher digital interactions associated with greater reductions in HbA1c and weight. The hybrid approach proves more effective than digital-only interventions, emphasizing the need for comprehensive, end-to-end solutions in diabetes care.
糖尿病是一个全球性的健康挑战，影响着 5.37 亿人。传统的管理方法依赖于定期的诊所就诊，但包括远程监测在内的技术进步带来了变革性的变化。远程医疗提高了可及性、便利性、依从性和血糖控制水平。挑战包括建立信任和面对面互动的限制。将远程监测与面对面医疗相结合，创造了一种混合方法。本研究评估了这种方法对 3 个月以上的 2 型糖尿病患者的影响。
这是一项回顾性病例对照观察研究。纳入标准包括先前的 2 型糖尿病诊断和至少 3 个月的 GluCare 模型期，期间有两次物理就诊。病例组患者进行门诊就诊、每两周使用应用程序一次并每月进行体重读数。对照组仅进行门诊就诊。测量的结果包括 HbA1c、血脂谱、心血管风险、eGFR、尿白蛋白/肌酐比、尿酸和 CRP。
病例组的 HbA1c 显著改善（-2.19%），尤其是基线水平较高的患者。体重、BMI、LDL、总胆固醇和心血管风险也有所改善。对照组的改善较小。更高的数字互动与更好的结果相关。进行了≥11 次互动的患者，HbA1c（-2.38%）和体重（-6.00kg）显著下降。
GluCare.Health 混合模型在 2 型糖尿病管理中显示出有前景的结果。将门诊咨询与持续的远程监测相结合，可显著改善血糖控制和临床参数。该研究强调了患者参与以实现积极结果的重要性，更高的数字互动与 HbA1c 和体重的更大降幅相关。混合方法比仅数字干预更有效，强调了在糖尿病护理中需要全面、端到端的解决方案。
